Pfizer’s Avagliano Joins G1 Therapeutics as Chief Business Officer

G1 Therapeutics (NASDAQ: [[ticker:GTHX]]) has tapped Mark Avagliano to become its chief business officer. Avagliano joins the Research Triangle Park, NC-based cancer drug developer from Pfizer (NYSE: [[ticker:PFE]]), where he was vice president of corporate development. Lead G1 drug candidate trilaciclib, which has been tested in small-cell lung cancer and metastatic triple-negative breast cancer, is being prepared for submission to the FDA for review.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.